Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Revinty Ellipta, Fluticasone Furoate / Vilanterol, Asthma, Date of Authorisation: 02/05/2014, Revision: 16, Status: Authorised
Case Medical Research
doi 10.31525/cmr-962c34
Full Text
Open PDF
Abstract
Available in
full text
Date
May 21, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Lenvima, Lenvatinib, Thyroid Neoplasms, Date of Authorisation: 28/05/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Rebetol, Ribavirin, Hepatitis C, Chronic, Date of Authorisation: 06/05/1999, Revision: 32, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Colobreathe, Colistimethate Sodium, Cystic Fibrosis, Date of Authorisation: 13/02/2012, Revision: 10, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Pixuvri, Pixantrone Dimaleate, Lymphoma, Non-Hodgkin, Date of Authorisation: 10/05/2012, Revision: 19, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Tadalafil Mylan, Tadalafil, Erectile Dysfunction, Date of Authorisation: 21/11/2014, Revision: 8, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): DuoResp Spiromax, Budesonide / Formoterol, Pulmonary Disease, Chronic Obstructive,Asthma, Date of Authorisation: 28/04/2014, Revision: 7, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Duloxetine Lilly, Duloxetine, Neuralgia,Diabetic Neuropathies, Date of Authorisation: 08/12/2014, Revision: 4, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Pregabalin Pfizer, Pregabalin, Anxiety Disorders,Epilepsy, Date of Authorisation: 10/04/2014, Revision: 13, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Farydak, Panobinostat, Multiple Myeloma, Date of Authorisation: 28/08/2015, Revision: 6, Status: Authorised
Case Medical Research
